Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.

Trial Details

NCT ID
NCT05985954
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Cetuximab
  • Ulixertinib
  • Encorafenib
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients must meet all of the inclusion criteria to be eligible:
  • Provision of signed Informed Consent prior to any screening procedures being performed.
  • Non-English speaking patients will be eligible for participation with involvement of the MD Anderson Language Assistance department in the informed…
  • Individuals lacking the ability, based on reasonable medical judgment, to understand and appreciate the nature and consequences of participation in…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →